Collaboration and Licensing Agreements - Narrative (Details) $ in Millions, ¥ in Billions	1 Months Ended					3 Months Ended		6 Months Ended			53 Months Ended
	Nov. 30, 2019 USD ($) item segment	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Nov. 30, 2017 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2022 CAD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2022 USD ($)	Jun. 30, 2022 JPY (¥)	Apr. 11, 2022 USD ($) payment_tranche
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue						$ 2,526,000	$ 1,313,000	$ 2,994,000		$ 7,895,000
Cost of revenue						138,000	0	223,000		1,000,000
License
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue						10,000	3,000	14,000		5,005,000
Product Supply Revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue						952,000	0	966,000		126,000
2019 KKC Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue						0	1,300,000	0		2,800,000
2019 KKC Agreement | KKC
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront license fees	$ 10,000,000
First installment of upfront license fees	$ 5,000,000
Term of payment of license fee, first installment	30 days
Second installment of upfront license fees	$ 5,000,000
Term of agreement	2 years
Number of amendments | segment	3
2017 KKC Agreement | License
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue						0	0	0		5,000,000	$ 10,000,000
2017 KKC Agreement | Product Supply Revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue						952,000	0	966,000		126,000
2017 KKC Agreement | KKC
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront license fees				$ 30,000,000
Potential development milestones				$ 55,000,000
Potential commercialization milestones						62,300,000		62,300,000				¥ 8.5
Fee receivable for reduction in royalty rate													$ 40,000,000
Number of payment tranches for fee receivable for reduction in royalty rate | payment_tranche													2
Fosun Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue						0	0	0		0
Fosun Agreement | Fosun Pharma
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential development milestones						3,000,000		3,000,000
Upfront payment received			$ 12,000,000
Potential development and commercialization milestones								$ 113,000,000
Threshold percentage of net sales for tiered royalties								20.00%	20.00%
Knight Agreement | Knight
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential development milestones						700,000		$ 700,000
Upfront payment received		$ 2,300,000
Potential development and commercialization milestones								17,200,000	$ 22.2
AZ Termination Agreement | AstraZeneca
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty revenue					10.00%
Percentage of non-royalty revenue					20.00%
Maximum potential payment per agreement					$ 75,000,000
Aggregate cost of revenue recognized						11,900,000		11,900,000
Aggregate amount paid						11,600,000		11,600,000
Cost of revenue						$ 200,000	$ 0	$ 300,000		$ 1,000,000
Minimum | 2019 KKC Agreement | KKC
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of separate collaborative agreements | item	1